The Great Valuation Bifurcation: 13x for IP, 5x for Bodies
In 2025, the middle ground in IT services M&A has evaporated. We are witnessing a stark bifurcation in valuation multiples driven entirely by revenue quality, not revenue volume. For PE Operating Partners managing portfolio companies in the $10M-$50M EBITDA range, the aggregate revenue number in the CIM is increasingly irrelevant compared to the composition of that revenue.
According to Q1 2025 data, the spread between business models has widened to historic levels:
- Premium Assets (Specialized IT Consulting & Digital Transformation): Trading at a median of 13.0x - 13.6x EBITDA. These firms possess defensible IP, high-value partner ecosystems (Salesforce, ServiceNow), and project backlogs exceeding 9 months.
- Standard MSPs (Managed Services): Trading at 8.8x - 10.2x EBITDA. The premium here (up to 12x) is reserved for those with >70% recurring revenue and customer retention rates above 90%.
- Commoditized Staff Augmentation: Trading at 4.5x - 6.0x EBITDA. The market has brutally corrected for "body shop" models. If your portfolio company relies on Time & Materials contracts, buyers are pricing it as a low-margin recruiting firm, not a technology consultancy.
The danger for Portfolio Paul lies in the "blended" messy middle. A $20M EBITDA firm with 40% of its revenue from low-margin staff augmentation will not trade at a weighted average. In 2025 diligence, buyers are applying the lower multiple to the entire entity, arguing that the low-quality revenue dilutes the strategic value of the whole. To unlock the 12x exit, you must ruthlessly divest or restructure these low-value revenue streams 18 months before the sale.
The Structure Trap: Why Your "Headline Price" is a Fiction
The headline multiples of 2021 are gone, replaced by what I call "Structure-Heavy" deal terms. With SOFR holding steady around 4.5% and leverage becoming expensive, buyers are using earnouts not just to bridge valuation gaps, but to de-risk the entire transaction. The result? A purchase price that looks like 10x on the LOI but functions like 6x in cash-at-close.
The data on this is sobering. According to the 2025 SRS Acquiom Deal Terms Study, earnouts are now present in a significant portion of private-target deals, yet they pay out on average just 21 cents on the dollar. This is the "Earnout Trap." When a buyer offers you a $100M exit composed of $60M cash and $40M in earnouts, you are statistically likely to collect only $68.4M total. The remaining $31.6M is a phantom number used to stroke the founder's ego while protecting the buyer's IRR.
We are seeing Private Equity sponsors increasingly favor deferred cash considerations and seller notes over massive earnouts to avoid the post-close integration friction that earnouts create. However, if an earnout is unavoidable, you must structure it on revenue triggers, not EBITDA triggers. EBITDA can be manipulated by the buyer's post-close cost allocations (the "corporate management fee"); revenue is harder to hide. If you are preparing an exit, you need to understand the mathematics of the 21-cent dollar and negotiate for higher cash-at-close, even if it means accepting a lower headline valuation.
The "Quality of Earnings" Buzzsaw
In 2025, Quality of Earnings (QofE) reports are no longer just accounting exercises; they are strategic weapons used to re-trade the deal weeks before close. The number one deal killer we see today is Customer Concentration disguised as "Key Accounts."
Buyers are aggressively normalizing EBITDA for "at-risk" revenue. If a single client represents >15% of Gross Profit, or if the top 5 clients represent >40%, buyers are not just highlighting it as a risk—they are removing that EBITDA from the valuation multiple entirely. I recently watched a $15M EBITDA deal crumble because the "recurring" revenue from their largest client was actually a series of 12-month renewable SOWs that required a re-win every year. The buyer reclassified this as "project revenue," slashed the multiple from 11x to 7x, and the deal died.
To defend your valuation, you must perform a Revenue Quality Audit before you ever hire a banker. You need to convert "re-occurring" revenue into legally binding "recurring" contracts with auto-renew clauses and price escalators. If you wait for the buyer's KPMG team to find these holes, you have already lost the negotiation.
